Simple blood test may predict immunotherapy success in lung cancer

NCT ID NCT07363811

Recruiting now Knowledge-focused Sponsor: Necmettin Erbakan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking at whether large granular lymphocytes (LGLs), a type of immune cell, can predict how well patients with advanced non-small cell lung cancer respond to the immunotherapy drug nivolumab. Researchers will measure LGL levels in 50 patients before and during treatment and compare them to tumor response and survival. The goal is to find a simple blood test that helps guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which lung cancer patients will benefit most from nivolumab, leading to more personalized treatment.
What could go wrong: This is a small, early observational study (50 participants) that only looks for a link between LGLs and outcomes. It does not test a new treatment, so it may not change practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Necmettin Erbakan University Faculty of Medicine, Department of Medical Oncology
RECRUITING

Konya, Meram, 42090, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.